Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.  LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line EGFR mutation-positive, advanced, metastatic NSCLC patients, and the first to use pemetrexed/cisplatin as a comparator in this population.

The presentation of the LUX-Lung 3 trial will shed light on a distinct and specific NSCLC patient population, those with EGFR mutations.  EGFR mutations occur in 10 to 15 percent of NSCLC patients, and are well-established predictive biomarkers that provide specific targets for therapeutic intervention in NSCLC.  TitleLead AuthorPresentation detailsLUX-Lung 3: A randomized,
open-label, phase III study of
afatinib versus pemetrexed and
cisplatin as first-line treatment for
patients with advanced
adenocarcinoma of the lung
harboring EGFR-activating mutations.

 

James Chih-Hsin Yang, MD, PhD

 

 

 

Oral Abstract #LBA7500

Date: Monday, June 4
Time: 3:00 PM-3:15 PM CDT

 

 

 "We are excited to share the results of our pivotal LUX-Lung 3 trial, the largest and most robust ever conducted in EGFR mutation-positive patients," said Berthold Greifenberg, M.D., Vice President, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.  "We are continuously advancing the development of our oncology pipeline and look forward to opportunities to contribute to the bo
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... SHANGHAI , July 1, 2015 Qiming ... Hu to Managing Partner effective immediately. ... He has lead and participated in many Qiming healthcare ... leaders in the Chinese market. Qiming, s success in ... and he has distinguished himself with his outstanding advocacy ...
(Date:7/1/2015)... , July 1, 2015 Lupin ... Bring Total Number of MPP Sub-licensees to Fourteen ... Patent Pool (MPP) announced the rapid expansion of its network ... than 50 projects to develop MPP-licensed antiretrovirals (ARVs). New companies ... (DTG), a promising new HIV medicine the MPP licensed from ...
(Date:7/1/2015)... Boston Scientific Corporation (NYSE: BSX ) will webcast its ... second quarter ended June 30, 2015 on Thursday, July 23, ... be hosted by Mike Mahoney , president and chief ... and chief financial officer. A live webcast of ... website. Webcast registration is available on the Investor Relations section ...
Breaking Medicine Technology:Qiming Announces the Promotion of William Hu to Managing Partner 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
... Reportlinker.com announces that a new market research report is available in its catalogue: , ... Market Analysis 2010-2025 , , , ... Reports details , ... in this diverse market with high, growing demand worldwide? , , , ...
... , May 4 Emdeon Inc. (NYSE: ... revenue and payment cycle management solutions, today announced a ... solutions company delivering more accurate, timely and comprehensive data ... will be able to offer its 1,200 healthcare payer ...
Cached Medicine Technology:Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 2Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 3Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 4Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 5Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 6Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 7Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 8Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 9Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 10Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 11Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 12Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 13Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 14Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 15Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 16Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 17Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality 2Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality 3Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality 4Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality 5
(Date:7/1/2015)... ... July 01, 2015 , ... Sir Fazle Hasan Abed, BRAC’s founder ... today. Sir Fazle has been recognised for his outstanding contribution to enhancing the world's ... Quinn, President of the World Food Prize Foundation, announced this year’s winner at a ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... new members to their industry leading Scientific Advisory Board. LRF’s volunteer Scientific Advisory ...
(Date:7/1/2015)... Tokyo, Japan (PRWEB) , ... July 01, 2015 ... ... August 2015 of a new extraction plant for Linablue®, Spirulina-derived natural blue food ... Earthrise Nutritionals, LLC, the DIC Group’s U.S. Spirulina* production base, began in May ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... cancer enterprise of Hospital Corporation of America (HCA), as it further expands its ... announced today. , With this new partnership, OncLive’s editorial and marketing teams ...
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show hosted by ... 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event will ... zoo, an Elvis impersonator, a silent auction and concessions. , Horses and riders from ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... on gum bacteria, scientists had been able to use ... the oral cavity. ,The dental samples obtained from ... light (380 to 520nm). The light had selectively killed ... dental plaque samples obtained from patients. Medium strength light ...
... a research covering 218 diabetic patients and 799 non-diabetic ... scientists of Epidemiologic Research and Information Center, Seattle, US ... having a urinary tract infection for women who have ... annual follow up of testing for hemoglobin A1c, urine ...
... drug market watchdog Food and Drug Administration had announced a ... the class of non-steroidal anti-inflammatory drugs that are sold with ... withdrawal of the drug Bextra (valdecoxib) from Pfizer, Inc. ... as FDA had reports that the overall risk associated with ...
... pattern of rising early from bed in the mornings have ... ,The behavior is called familial advanced sleep phase syndrome ... said to be the phenotype of the gene PER2. The ... phosphorylation site in the casein kinase I (CKI) domain of ...
... Institute Maryland USA had found out a gene that is ... syndrome. ,The disease is caused by a point ... of the major genes that lead to the physiology of ... individual with the disease have severe abnormalities in the nuclear ...
... had pointed out that excessive exposure to television at the ... behavior.// ,A child is considered to be a bully ... be done by actual physical attack on others or by ... not read aloud to their children, or provide them with ...
Cached Medicine News:
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
Medicine Products: